Citadel Advisors
SGYP

Citadel Advisors’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Citadel Advisors’s Portfolio SGYP Stock Details SGYP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-175,900
Closed -$20K – 10278
2018
Q4 		$20K Buy
175,900
+45,600
+35% +$29.9K ﹤0.01% 8762
2018
Q3 		$222K Buy
130,300
+88,700
+213% +$159K ﹤0.01% 8053
2018
Q2 		$72K Sell
41,600
-62,800
-60% -$109K ﹤0.01% 8360
2018
Q1 		$191K Sell
104,400
-210,800
-67% -$445K ﹤0.01% 7391
2017
Q4 		$703K Buy
315,200
+200,000
+174% +$497K ﹤0.01% 5164
2017
Q3 		$334K Sell
115,200
-29,400
-20% -$100K ﹤0.01% 5899
2017
Q2 		$643K Sell
144,600
-42,300
-23% -$174K ﹤0.01% 4762
2017
Q1 		$871K Buy
186,900
+106,300
+132% +$616K ﹤0.01% 4205
2016
Q4 		$491K Buy
80,600
+7,600
+10% +$39.7K ﹤0.01% 4924
2016
Q3 		$402K Buy
+73,000
New +$342K ﹤0.01% 5196

Other funds holding SGYP

TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Citadel Advisors's SGYP Position: Q1 2019 in Review

Citadel Advisors sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2019, closing a stake of 547,822 shares — an estimated $62K sold.

Citadel Advisors first reported a position in SGYP in Q1 2014 and held it in 18 quarters. The position peaked at $27.5M in Q1 2017. 12 funds tracked by Wall St. Rank hold SGYP as of Q1 2019.

  • Citadel Advisors reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2019 after selling out during the quarter.
  • Citadel Advisors sold 547,822 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2019, an estimated $62K.
  • Citadel Advisors first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q1 2014 and held it in 18 quarters.
  • Citadel Advisors's Synergy Pharmaceuticals, Inc Common Stock position peaked at $27.5M in Q1 2017.
  • 12 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2019.

Based on Citadel Advisors's 13F filing for Q1 2019, filed 15 May 2019.